Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 501 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR 6 of the biggest good news cancer stories of 2021 December 15, 2021 6 Things That Helped Me Think Positively During Cancer: A Patient... August 16, 2022 FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute... October 26, 2020 What to Say to Someone With Cancer: A Patient Perspective July 14, 2022 Load more HOT NEWS Foodie Fridays-Gazpacho: A Favorite Summer Soup One Million Masks Donated! But GreaterGood Will Continue to Help Where... Foodie Friday: Couscous Salad ΠΩΣ ΠΡΟΚΑΛΕΙΤΑΙ
